Royalty Pharma Declares Fourth Quarter 2024 Dividend
The board of directors has announced a dividend for the fourth quarter of 2024, set at $0.21 per Class A ordinary share. This reflects the company's strong financial performance and commitment to rewarding its shareholders.
Dividend Payment Schedule
This dividend is scheduled to be paid on December 10, 2024, to shareholders who are on record by the close of business on November 15, 2024. Such regular distributions are a testament to Royalty Pharma’s financial health and operational success.
Understanding Royalty Pharma’s Business Model
Royalty Pharma was founded in 1996 and quickly became the premier buyer of biopharmaceutical royalties. It plays a crucial role in funding the innovation necessary for new therapies by collaborating with a diverse range of organizations. This includes not only small and mid-cap biotechnology firms but also major pharmaceutical corporations and academic institutions.
Portfolio Overview
The company's impressive portfolio encompasses royalties from over 35 commercial products. High-profile therapies like Vertex’s Trikafta and GSK’s Trelegy illustrate its significant presence in the industry. Furthermore, Royalty Pharma not only supports innovative products but also ensures that it reaps benefits from established successful treatments.
Keys to Funding Innovation
Royalty Pharma engages in funding both directly and indirectly. They partner with innovators to co-fund late-stage clinical trials and new product launches while acquiring existing royalties from developers, ensuring a steady influx of revenue from cutting-edge therapies. This strategy cultivates an ecosystem of growth and innovation essential in today's biopharmaceutical landscape.
Commitment to Shareholders
The recent dividend announcement reflects Royalty Pharma's steadfast dedication to its investors. By distributing dividends consistently, it demonstrates a commitment to providing shareholder value while also solidifying their reputation as a stable and reliable investment in the industry. The $0.21 dividend is a notable figure and is part of their ongoing policy to reward shareholders for their support.
Contacting Royalty Pharma
For questions regarding this announcement or for investor relations inquiries, individuals can contact Royalty Pharma directly. The company is available at +1 (212) 883-6637. For further assistance, inquiries can be directed to their investor relations email at ir@royaltypharma.com.
Frequently Asked Questions
What is the amount of the dividend declared by Royalty Pharma?
The dividend amount declared for Q4 2024 is $0.21 per Class A ordinary share.
When will the dividend be paid?
The dividend is scheduled to be paid on December 10, 2024, to shareholders on record as of November 15, 2024.
How does Royalty Pharma support innovation?
Royalty Pharma supports innovation by co-funding clinical trials and new product launches, as well as acquiring existing royalties from other innovators.
What types of products does Royalty Pharma hold royalties for?
Royalty Pharma’s portfolio includes royalties from over 35 commercial products, including leading therapies from various pharmaceutical companies.
How can I contact Royalty Pharma for investor relations?
Investors can contact Royalty Pharma at +1 (212) 883-6637 or email them at ir@royaltypharma.com.
